A New Wave in Neurodegeneration Treatment: How Clene’s CNS—Gold Nano-Particle Program (CNM-Au8®) Aims to Target Disease Progression in ALS, MS, and PD.
Wednesday, December 10, 2025
11:00 AM – 12:00 PM ET
The brain’s energy demands create an inherent vulnerability to metabolic changes, particularly in populations of neurons that utilize large amounts of energy to function, such as those associated with neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease (PD).
Clene Nanomedicine is developing a revolutionary approach to treating ALS, MS, and PD, which augments bioenergetic deficits and reduces oxidative stress and protein aggregation, thereby restoring and protecting neurological function.
Join Jason Kolbert, Head of Research at D. Boral Capital, and Robert Etherington, CEO of Clene Nanomedicine, for an in-depth discussion of Clene’s CNS—Gold Nano-Particle (CNM-Au8®) program, the science behind targeting bioenergetic failure, and the company’s advancing work in ALS and other neurodegenerative diseases. This fireside conversation will highlight recent statistically significant ALS biomarker results, clinical learnings, and the key regulatory and research milestones shaping Clene’s path forward, including upcoming trial preparations.
Don’t miss this opportunity to hear directly from the CEO of Clene Nanomedicine as he shares new insights, key company updates, and addresses how they are advancing a pipeline of nanotherapeutics to address high unmet medical needs.
Jason Kolbert
Head of Research
D. Boral Capital











